Evidence map›Paper›PMID 39257149›Full record

ArticleCurrent pharmaceutical biotechnology2025

Houda Haddad, Klinger Antonio da Franca Rodrigues, Houcemeddine Othman, Leiz Maria Costa Veras, Raiza Raianne Luz Rodrigues, Ines Ouahchi, Bouraoui Ouni, Amira Zaϊri

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Houda HaddadBIOLIVAL Laboratory, Higher Institute of Biotechnology of Monastir ISBM, University of Monastir, 5000 Monastir, Tunisia.
Klinger Antonio da Franca RodriguesLaboratory of Infectious Diseases, Ladic, Campus Ministro Reis Velloso, Federal University of Delta do Parnaíba, 64202-020, Brazil.
Houcemeddine OthmanLaboratory of Cytogenetics and Reproductive Biology, CHU Farhat Hached, 4000 Sousse, Tunisia.
Leiz Maria Costa VerasBiodiversity and Biotechnology Research Center, BIOTEC, Federal University of Piauí, Parnaíba, PI, Brazil.
Raiza Raianne Luz RodriguesLaboratory of Infectious Diseases, Ladic, Campus Ministro Reis Velloso, Federal University of Delta do Parnaíba, 64202-020, Brazil.
Ines OuahchiBiodiversity Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat Hached University Hospital, 4000 Sousse, Tunisia.
Bouraoui OuniPharmacology department, Faculty of Medicine, University of Sousse, 4002 Sousse, Tunisia.
Amira ZaϊriBiochemistry Department, Faculty of Medicine, University of Sousse, 4002 Sousse, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeishmaniasis is responsible for approximately 65,000 annual deaths. Various Leishmania species are the predominant cause of visceral, cutaneous, or mucocutaneous leishmaniasis, affecting millions worldwide. The lack of a vaccine, emergence of resistance, and undesirable side effects caused by antileishmanial medications have prompted researchers to look for novel therapeutic approaches to treat this disease. Antimicrobial peptides (AMPs) offer an alternative for promoting the discovery of new drugs.

methodsIn this study, we detail the synthesis process and investigate the antileishmanial activity against

resultsAll examined derivatives displayed concentration-dependent antileishmanial effect at low concentrations. Their effectiveness varied according to the peptide's proprieties. Notably, peptides with higher levels of charge demonstrated the most pronounced activities. Cytotoxicity assays showed that all the tested peptides were not cytotoxic compared to the tested conventional drug. The structure-function relationships demonstrated that the charged N-terminus could be responsible for the antileishmanial effect observed on promastigotes.

conclusionCollectively, these results propose that dermaseptins (DS) might offer potential as promising candidates for the development of effective antileishmanial therapies.

Indexed as

Amphibian ProteinsAntimicrobial Cationic PeptidesAntiprotozoal AgentsLeishmania braziliensisAnimalsCell SurvivalComputer SimulationMacrophagesMiceModels, MolecularRAW 264.7 CellsStructure-Activity RelationshipAmphibian ProteinsAntimicrobial Cationic PeptidesAntiprotozoal Agentsdermaseptinanalogsantileishmanial activityDermaseptin B2dermaseptin S4Leishmania (Viannia) braziliensispromastigotes.

Identifiers

PMID39257149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.